Citations with the tag: MYLAN Pharmaceuticals Inc
Results 51 - 100
- Epilepsy Update.
// PharmaWatch: CNS; Feb2012, Vol. 11 Issue 2, p6
The article offers news briefs related to epilepsy. Mylan Inc.'s subsidiary Mylan Pharmaceuticals Inc. has received final approval from the Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Extended-release (ER) tablets. UCB SA has announced...
// Medical Marketing & Media; Apr2013, Vol. 48 Issue 4, p17
The article offers news briefs on the plan of Roche to slash costs of its cancer treatment drug Herceptin, the plan of Royalty Pharma to enter drug manufacturing, and the acquisition of Strides Arcolab's Indian manufacturer Agila Specialties by Mylan Pharmaceuticals Inc.
- MYLAN PHARMACEUTICALS, INC. V. THOMPSON.
// Berkeley Technology Law Journal; Annual Review 2002, Vol. 17 Issue 1, p155
Presents the legal case involving Mylan Pharmaceuticals Inc. v. Bristol-Myers Squibb Co. on the approval of drug products in the U.S. Use of generic drug; Treatment of anxiety through buspirone hydrochloride; Lists of the second patent from the Orange Book.
- TOP 20 GENERIC PLAYERS by No. of prescriptions dispensed.
// Drug Store News; 2/17/2003, Vol. 25 Issue 2, p39
Features the top 20 generic drug companies in the U.S. Watson Pharmaceuticals Inc.; Mylan Pharmaceuticals Inc. ; Geneva Pharmaceuticals Inc.
- Depakote ER goes generic.
// Pharmaceutical Representative; Apr2009, Vol. 39 Issue 4, p10
The article reports on the marketing approval attained by Wockhardt USA and Mylan Pharmaceuticals Inc. for Depakote ER. It mentions that the two pharmaceutical companies will have their 180 days in marketing the newly FDA-approved medication. Moreover, this drug is intended to cure and alleviate...
- THIS MONTH'S HIGHLIGHTS.
// PharmaWatch: CNS; Aug2008, Vol. 7 Issue 8, p2
The article offers news briefs related to pharmaceutical industry in the U.S. Eli Lilly & Co. has announced that the Food and Drug Administration (FDA) has approved Cymbalta for the management of fibromyalgia. Mylan Pharmaceuticals Inc. has also received the final approval from the FDA for its...
- News Focus.
// Pharmaceutical Representative; Aug2005, Vol. 35 Issue 8, p10
Reports developments in the pharmaceutical industry in the U.S. Plan of Wyeth Pharmaceuticals to reduce its primary care and women's health sales force; Implementation of the restructuring plan by Wyeth through a regional pilot program; Decision of Mylan Laboratories to close its Mylan Bertek...
- Growing and Giving Back.
Kasey, Pam // State Journal (WV); 6/1/2012, Vol. 28 Issue 22, p1
The article reports on the contributions of pharmaceutical company Mylan Pharmaceuticals Inc. in Morgantown, West Virginia on the state's economy. It states that the company has created 3,000 jobs of the total private non-farm employment of nearly 40,000 in Monongalia County. Ken Busz of...
- Merck claims Mylan infringement.
Kasey, Pam // Medical Marketing & Media; Apr99, Vol. 34 Issue 4, p28
Reports on the patent infringement lawsuit filed by Merck against Mylan Pharmaceuticals Inc.
- New Products Hit the Market.
Kasey, Pam // Chain Drug Review; 5/21/2012, Vol. 34 Issue 9, p70
The article informs about the launch of several drugs in the U.S. including doxycycline hyclate delayed-release tablets by Mylan Pharmaceuticals Inc., olanzapine tablets by Dr. Reddy's Laboratories Ltd., dexlansoprazole capsules by Par Pharmaceutical Inc.
- Endo Pharmaceuticals files lawsuit against Mylan.
Kasey, Pam // PharmaWatch: CNS; Oct2011, Vol. 10 Issue 10, p23
The article reports on the lawsuit filed by Endo Pharmaceuticals Inc. against Mylan Pharmaceuticals Inc. in connection with the filing of an abbreviated new drug application (ANDA).
- Pharma: Other News To Note.
Kasey, Pam // BioWorld Today; 6/11/2012, Vol. 23 Issue 112, p8
The article reports on the settlement of a dispute of Mylan Pharmaceuticals Inc. with Teva Pharmaceuticals USA Inc. in line with the suit filed by Mylan against the U.S. Food and Drug Administration (FDA) related to its abbreviated new drug application for Modafinil tablets.
- High court won't revisit public-figure issue.
Kasey, Pam // Hollywood Reporter; 10/3/95, Vol. 339 Issue 12, p6
Reports that the United States Supreme Court has rejected a request to consider American Cyanamid as a public figure in the lawsuit against Mylan Pharmaceuticals.
- Pharma: Other News To Note.
Kasey, Pam // BioWorld Today; 5/20/2013, Vol. 24 Issue 96, p7
This section offers news briefs in the U.S. pharmaceutical industry as of May 20, 2013 including Bristol-Myers Squibb Co.'s plan to voluntary delist its two dollars convertible preferred stock from the New York Stock Exchange, the distribution of the Fenofibrate Tablets from Mylan...
- Pharma & Fine Chemicals: Market Briefs.
Kasey, Pam // Chemical Market Reporter; 01/24/2000, Vol. 257 Issue 4, p12
Provides news briefs on pharmaceutical and fine chemical industry as of January 24, 2000. Marketing agreement between Mylan Laboratories Inc. and Bertek Pharmaceuticals Inc.; Approval for Tequin quinolone antibiotic from Bristol-Myers Squibb Co.; Human clinical trial for polyglutamate...
- Pfizer: Lipitor wins a new indication.
Kasey, Pam // PharmaWatch: Monthly Review; Nov2005, Vol. 4 Issue 11, p16
The article reports that the U.S. Food and Drug Administration (FDA) has granted approval for Mylan Pharmaceuticals Inc. to market a generic version of Pfizer Inc.'s drug, Norvasc. As Mylan is the first to file for generic approval to market a generic version of Norvasc in the U.S., the company...
- Pfizer: the pressure is on for Norvasc.
Kasey, Pam // PharmaWatch: Monthly Review; Nov2005, Vol. 4 Issue 11, p17
The article reports that Mylan Pharmaceuticals Inc. has received the approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.'s blockbuster blood pressure drug Norvasc. As Mylan is the first to file for generic approval to market a generic version of...
- new products.
Kasey, Pam // Dermatology Times; Jan2010, Vol. 31 Issue 1, p64
The article evaluates several medical products including the generic acne tx from Mylan Pharmaceuticals Inc., Lipsovir drug for cold sores treament from Medivir AB, and TNS ceramide skin treatment cream from SkinMedica Inc.
- Mylan receives 'approvable letter' for apomorphine.
Kasey, Pam // PharmaWatch: CNS; August 2003, Vol. 2 Issue 8, p6
Reports on the acquirement of an approval by Bertek Pharmaceuticals Inc. for its apomorphine hydrochloride injection in the U.S. Submission of additional information by the firm to the Food and Drug Administration; Use of the drug in Parkinson's disease; Administration of the drug.
- COMPANY SPOTLIGHT - Mylan Laboratories.
Kasey, Pam // PharmaWatch: CNS; Jul2008, Vol. 7 Issue 7, p17
The article presents a company profile of the U.S.-based pharmaceutical firm Mylan Laboratories Inc. (Mylan). Mylan has three principal subsidiaries including Mylan Pharmaceuticals Inc. (MPI), UDL Laboratories Inc. (UDL) and Mylan Technologies Inc. (Mylan Tech), each having their own respective...
- CNS News Round-Up.
Kasey, Pam // PharmaWatch: CNS; Dec2008, Vol. 7 Issue 12, p2
The article offers world news briefs related to the pharmaceutical industry. The Mylan Pharmaceuticals Inc. has received final approval to market its levetiracetam tablets in 250 milligram (mg), 500 mg and 750 mg formulations. AstraZeneca PLC has announced approval of Seroquel XR and Seroquel...
- CNS News Round-Up.
Kasey, Pam // PharmaWatch: Monthly Review; Dec2008, Vol. 7 Issue 12, p12
The article offers world news briefs related to pharmaceutical industry. Belgian biotechnology company UCB has told that the U.S. Food and Drug Administration has approved its new antiepileptic, Vimpat, for use as an add-on therapy in patients aged 17 and older. Mylan Pharmaceuticals has also...
- REPORTERS Notebook.
Kasey, Pam // Drug Store News; 11/12/2007, Vol. 29 Issue 14, p22
The article offers news briefs related to the pharmaceutical industry in the U.S. Mylan and its subsidiary, Mylan Pharmaceuticals Inc., have signed a marketing agreement with Glaxo-SmithKline for paroxetine hydrochloride extended-release tablets. Merck KgaA has decided to halt its research and...
- Importer of Controlled Substances; Notice Of Registration; Mylan Pharmaceuticals, Inc.
Rannazzisi, Joseph T. // Federal Register; 5/22/2012, Vol. 77 Issue 99, p30326
The article presents information on an application filed by Mylan Pharmaceuticals Inc. to the U.S. Drug Enforcement Administration to register it as an importer of the controlled substances including amphetamine, methadone and morphine.
- DERMATOLOGICAL DISORDERS.
Rannazzisi, Joseph T. // Monthly Prescribing Reference; Oct2009, Vol. 25 Issue 10, p106
The article offers information about pharmaceuticals used in treating dermatological disorders. It discusses the indications, precautions, interactions, adverse reactions, and supply of these drugs. They include retinoid Amnesteem from Mylan Pharmaceuticals Inc. for severe recalcitrant nodular...
- DERMATOLOGICAL DISORDERS.
Rannazzisi, Joseph T. // Monthly Prescribing Reference; Dec2009, Vol. 25 Issue 12, p114
The article offers information on several drugs for the treatment of dermatological disorders and discusses their indications, contraindications and precautions. Aczone from Allergan Inc. is a topical treatment for acne vulgaris and should be applied twice daily. Amnesteem from Mylan...
- DERMATOLOGICAL DISORDERS.
Rannazzisi, Joseph T. // MPR - Pharmacist's Edition; Fall2013, Vol. 7 Issue 3, p49
The article offers brief information on several dermatological agents for acne treatment including the Aczone from Allergan Pharmaceuticals Inc., the Amnesteem from Mylan Pharmaceuticals Inc. and the Benzac AC from Galderma SA.
- REPORTER'S NOTEBOOK.
Rannazzisi, Joseph T. // Drug Store News; 8/23/2004, Vol. 26 Issue 10, p53
Reports on developments in the pharmaceutical industry for the period ended August 23, 2004. U.S. Food and Drug Administration's approval of Pfizer's Lipitor (atorvastatin) as a supplement in reducing the risk of heart attacks; Abbott Laboratories' submission of a new drug application for...
- More Must Be Done to Help Bioscience Companies Grow.
Gregg, Derek // State Journal (WV); 3/11/2011, Vol. 27 Issue 10, p21
The article reports on the emerging of bioscience industry in West Virginia. According to BIO, the industry trade organization, the industry involves research and development of advance health care, environmental, agricultural, and industrial products. Also included are various biosciences...
- HITTING THE HEADLINES: BRIC Retains Pharma Investments.
Gregg, Derek // Pharmaceutical Technology Europe; Sep2012, Vol. 24 Issue 9, p10
The article reports that emerging countries continue to attract the pharmaceutical firms in Brazil, Russia, India and China (BRIC). It says that a recent poll in PharmTech.com revealed that 36% chosen Brazil as one of the countries most interested in expanding business operations, followed by...
- Mylan Pharmaceuticals.
Gregg, Derek // Drug Store News; 7/23/2001, Vol. 23 Issue 9, p44
Introduces Mylan Pharmaceuticals Incorporated's brand of buspirone hydrochloride tablets, an alternative to Bristol-Myers Squibb's BuSpar. Mechanics of its dosing flexibility; Advantage of the Mylan drug.
- New products.
STEIN, JULIANNE // Drug Topics; Oct2013, Vol. 157 Issue 10, p49
The article offers brief information on several over-the-counter (OTC) drugs including the Astagraf XL from Astellas Pharma US Inc., the nitroglycerin lingual spray from Perrigo Co. and the bupropion HCI extended-release (ER) tablets USP from Mylan Pharmaceuticals Inc.
- Mylan wins FDA approval for additional strengths of antipsychotic drug.
STEIN, JULIANNE // PharmaWatch: CNS; Sep2009, Vol. 8 Issue 9, p20
The article reports that U.S. Food and Drug Administration (FDA) approved the abbreviated new drug application (ANDA) for haloperidol tablets of the Mylan Pharmaceuticals Inc. It mentions that the approval of the haloperidol tablets adds strength to the Mylan's marketed haloperidol in various...
- Mylan signs settlement agreement with Wyeth for depression drug.
STEIN, JULIANNE // PharmaWatch: CNS; Jan2010, Vol. 9 Issue 1, p10
The article reports that Mylan Pharmaceuticals Inc. has entered into settlement and licensing agreements with Wyeth regarding the venlafaxine hydrochloride extended release capsules. The capsules are the generic version of Wyeth's Effexor XR capsules, a treatment for major depressive disorder....
- Mylan wins FDA approval for generic Risperdal tablets.
STEIN, JULIANNE // PharmaWatch: CNS; Nov2008, Vol. 7 Issue 11, p12
The article focuses on the approval received by Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc., from the U.S. Food and Drug Administration for its abbreviated new drug application of risperidone tablets USP, 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg. It pertains that risperidone tablets are...
- Depression Update.
STEIN, JULIANNE // PharmaWatch: CNS; Jan2009, Vol. 8 Issue 1, p9
The article offers depression related developments worldwide. The Food and Drug Administration (FDA) approved Mylan Pharmaceuticals Inc.'s abbreviated new Drug Application for veniafaxine hydrochloride. The FDA approved Watson Laboratories Inc.'s abbreviated New Drug Application for bupropion...
- Mylan wins FDA approval for generic Parkinson's drug.
STEIN, JULIANNE // PharmaWatch: CNS; Nov2009, Vol. 8 Issue 11, p6
The article reports on the approval of the abbreviated new drug application (ANDA) for Carbidopa and Levodopa tablets from Mylan Pharmaceuticals, a subsidiary of Mylan by the Food & Drug Administration. The drugs are the generic forms of Sinemet, a treatment for Bristol Myers Squibb's Parkinson....
- Licensing Update.
STEIN, JULIANNE // PharmaWatch: Biotechnology; Jul2008, Vol. 7 Issue 7, p16
The article provides updates on the licensing agreements among biotechnology companies. Noxxon Pharma AG has signed a licensing agreement with Eli Lilly and Co. regarding the discovery and development of Spiegelmers for the treatment of migraine. Debiopharm Group Co. agreed with its long-term...
- Mergers & Acquisitions Update.
STEIN, JULIANNE // PharmaWatch: Biotechnology; Jul2008, Vol. 7 Issue 7, p19
The article presents updates on mergers and acquisitions among bitechnology industries. The Novartis AG has signed an agreement to acquire Protez Pharmaceuticals Inc. Bristol-Myers Squibb (BMS) Co. and Kosan Biosciences Inc. have signed a merger agreement providing for the acquisition of a...
- product showcase.
STEIN, JULIANNE // Pharmacy Today; Jun2012, Vol. 18 Issue 6, p36
The article offers information related to approval of medicine. The U.S. Food and Drug Administration (FDA) announced the approval of avanafil, a phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction in men. UCB Inc. announced that FDA approved the formulation of rotigotine...
- CNS News Round-Up.
STEIN, JULIANNE // PharmaWatch: Monthly Review; Aug2008, Vol. 7 Issue 8, p13
The article offers updates on the approval of drugs for diseases related to central nervous system in the U.S. Eli Lily and Co. announced the approval of its Cymbalta for the management of fibromyalgia by the Food and Drug Administration (FDA). Mylan Pharmaceuticals Inc. received final approval...
- Top 10 Manufacturer Profiles.
STEIN, JULIANNE // Drug Store News; 2/16/2004, Vol. 26 Issue 2, p49
Presents the profiles of the top 10 generic drug manufacturers in the U.S. Teva Pharmaceuticals USA; Mylan Pharmaceuticals; Watson Pharma; Sandoz; Alpharma; Ivax; Mallinckrodt/Tyco; Qualitest Pharmaceuticals; Par Pharmaceutical; Barr Laboratories.
- The Industry.
STEIN, JULIANNE // Pharmaceutical Representative; Oct2010, Vol. 40 Issue 10, p7
The article offers news briefs related to pharmaceutical industries in the U.S. Kevin Kruse was appointed as the new executive director of the Society of Pharmaceutical and Biotech Trainers (SPBT). Bristol-Myers Squibb Co. has agreed to take on the biopharma company ZymoGenetics Inc. which hopes...
- Teva sues FDA over its refusal to ban generics during an 'exclusivity' period.
Dickinson, James G. // Medical Marketing & Media; Oct2004, Vol. 39 Issue 10, p16
Reports that Teva Pharmaceuticals has filed a suit against the U.S. Food and Drug Administration (FDA) over a decision not to ban authorized generics introduced during a first-to-file ANDA holder's 180-day exclusivity period. FDA's denial of a Teva petition and a similar petition from Mylan...
- Three new buys, three downgrades.
Dickinson, James G. // Dow Theory Forecasts;
The article offers news briefs related to business enterprises as of September 2013. It mentions that the net interest margin of Capital One Financial Corp. increased in the U.S. It mentions that growth in production and revenue, help in increasing the cash from operations in the U.S. It focuses...
- OTHER NEWS TO NOTE.
Dickinson, James G. // BioWorld Today; 10/8/2007, Vol. 18 Issue 195, p2
This section offers news briefs on the pharmaceutical industry in the U.S. as of October 2007. Genzyme Corp. gained approval to market Elaprase in Japan for the treatment of Hunter syndrome. The Memphis Bioworks Foundation has launched an accelerator seed fund seeking to encourage development of...
- Clinical Trials News.
Dickinson, James G. // Applied Clinical Trials; Jun2004, Vol. 13 Issue 6, p18
This article presents news briefs related to the pharmaceutical industry in the U.S. Research Triangle Park, North Carolina-based GlaxoSmithKline PLC has received the U.S. Federal Drug Administration (FDA) approval for a 25-mg children's dosage of GERD drug Zantac, ranitidine hydrochloride...
- Mylan files suit against Pittsburgh paper.
Dickinson, James G. // Drug Store News; 10/12/2009, Vol. 31 Issue 12, p34
The article reports on the lawsuit filed by generic-drug maker Mylan Pharmaceuticals Inc. against the newspaper Pittsburgh Post-Gazette in Pennsylvania. It notes that Mylan is alleged by the newspaper for ignoring and deleting computer warnings of drug quality or equipment problems in its plant...
- Mylan wins FDA approval for generic prostate cancer drug.
Dickinson, James G. // PharmaWatch: Cancer; Aug2009, Vol. 8 Issue 8, p14
The article reports on the approval of the Food and Drug Administration (FDA) on the abbreviated new drug application (ANDA) for bicalutamide 50 milligram (mg) tablets of Mylan Pharmaceuticals Inc. in the U.S. The tablets have been considered as the generic version of prostate cancer treatment...
- Depression Update.
Dickinson, James G. // PharmaWatch: CNS; Jul2008, Vol. 7 Issue 7, p10
The article provides updates concerning drug developments for depression. Sanofi-Aventis SA reported favorable results from a new study of its Ambien CR CIV tablets. Meanwhile, AstraZeneca PLC has applied for the approval of the Seroquel XR extended-release tablet for the treatment of major...